Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression

Area of Science:

• Neuroscience
• Psychiatry
• Medical Technology

Background:

• Preliminary findings suggested subcallosal cingulate gyrus deep brain stimulation (SCG DBS) efficacy in treatment-resistant depression (TRD).
• This study expands on initial results with an additional 14 patients, totaling 20 participants with extended follow-up.

Purpose of the Study:

• To evaluate the safety and efficacy of SCG DBS in patients with TRD.
• To assess the long-term benefits and associated brain metabolic changes following SCG DBS.

Main Methods:

• Twenty patients with TRD underwent serial assessments before and after SCG DBS.
• Response (≥50% reduction in HRSD-17) and remission (HRSD-17 ≤7) rates were determined.
• Positron emission tomography (PET) was used to examine metabolic changes associated with DBS.

Main Results:

• Early and progressive benefits were observed, with 60% of patients responding and 35% achieving remission at 6 months, sustained at 12 months.
• SCG DBS was associated with specific metabolic changes in cortical and limbic circuits implicated in depression.
• The procedure demonstrated a small number of serious adverse effects, with no permanent deficits.

Conclusions:

• SCG DBS is a relatively safe and effective treatment for TRD, providing significant and sustained improvement for at least one year.
• The therapy likely modulates brain networks involved in the pathophysiology of depression.
• Further double-blind studies are warranted before widespread clinical recommendation.